CIK 0001590877 · Non-accelerated filer<br>Smaller reporting company
REGENXBIO Inc.
Sign in to watch- Ticker
- RGNX
- Exchange
- Nasdaq
- Industry
- Biological Products, (No Diagnostic Substances)
- FY end
- Dec 31
- Entity type
- operating
- EIN
- 471851754
- Phone
- 240-552-8181
- Business address
- 9804 MEDICAL CENTER DRIVE, ROCKVILLE, MD, 20850
- Former names
- ReGenX Biosciences, LLC
- Open-market buys, last 90 days
- $949,381
- in 1 filing
- Open-market sales, last 90 days
- $0
- in 0 filings
Net +$949,381. Shares bought or sold at a price by officers, directors and 10% owners (Form 4 codes P and S). Grants, option exercises and tax withholding aren't counted.
Who's trading
90 days
Reading 100 more Form 4s from the SEC; this list fills in as they're read.
| Date | Insider | Transaction | Shares | Price | Value | Owned after |
|---|---|---|---|---|---|---|
| 2021-01-07 | Mills Kenneth T. President and CEO | Option exercise | +1,500 | $0.85 | $1K | 283,484 |
| 2021-01-07 | Mills Kenneth T. President and CEO | Sale | −1,500 | $50.01 | $75K | 281,984 |
| 2021-01-07 | Mills Kenneth T. President and CEO | Option exercise · Employee Stock Option (Right to Buy) | −1,500 | 47,670 | ||
| 2021-01-04 | Vasista Vittal Chief Financial Officer | Grant or award | +12,400 | 145,424 | ||
| 2021-01-04 | Vasista Vittal Chief Financial Officer | Grant or award · Stock Option (Right to Buy) | +56,200 | 56,200 | ||
| 2021-01-04 | Simpson Curran Chief Oper. & Tech. Officer | Grant or award | +13,800 | 17,748 | ||
| 2021-01-04 | Simpson Curran Chief Oper. & Tech. Officer | Grant or award · Stock Option (Right to Buy) | +62,300 | 62,300 | ||
| 2021-01-04 | PAKOLA STEVE Chief Medical Officer | Grant or award | +11,000 | 11,000 | ||
| 2021-01-04 | PAKOLA STEVE Chief Medical Officer | Grant or award · Stock Option (Right to Buy) | +49,700 | 49,700 | ||
| 2021-01-04 | Danos Olivier Chief Scientific Officer | Grant or award | +11,600 | 19,043 | ||
| 2021-01-04 | Danos Olivier Chief Scientific Officer | Grant or award · Stock Option (Right to Buy) | +52,500 | 52,500 | ||
| 2021-01-04 | Christmas Patrick J. Chief Legal Officer | Grant or award | +13,800 | 16,372 | ||
| 2021-01-04 | Christmas Patrick J. Chief Legal Officer | Grant or award · Stock Option (Right to Buy) | +62,500 | 62,500 | ||
| 2021-01-04 | Mills Kenneth T. President and CEO | Grant or award | +40,984 | 281,984 | ||
| 2021-01-04 | Mills Kenneth T. President and CEO | Grant or award · Stock Option (Right to Buy) | +185,167 | 185,167 | ||
| 2020-12-28 | Mills Kenneth T. President and CEO | Option exercise | +6,500 | $0.85 | $6K | 247,500 |
| 2020-12-28 | Mills Kenneth T. President and CEO | Sale | −4,647 | $48.47 | $225K | 242,853 |
| 2020-12-28 | Mills Kenneth T. President and CEO | Sale | −1,853 | $49.16 | $91K | 241,000 |
| 2020-12-28 | Mills Kenneth T. President and CEO | Option exercise · Employee Stock Option (Right to Buy) | −6,500 | 49,170 | ||
| 2020-12-24 | Vasista Vittal Chief Financial Officer | Sale | −3,376 | $50.00 | $169K | 133,024 |
Page 20 of 25 · 494 trades